Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Stay informed about the latest developments from Belite Bio Inc, a clinical-stage biopharmaceutical company advancing novel oral therapies for retinal degenerative diseases and metabolic disorders. This news feed aggregates press releases, regulatory announcements, clinical trial updates, and market-moving events related to BLTE stock and the company's drug development programs.
Belite Bio focuses on developing treatments for conditions with significant unmet medical needs, including Stargardt disease type 1 (the most common inherited retinal dystrophy) and geographic atrophy (advanced dry age-related macular degeneration). The company's lead product candidate, Tinlarebant, represents a first-in-class oral RBP4 antagonist designed to reduce the accumulation of toxic bisretinoids that cause progressive vision loss in these blinding conditions.
Key news topics covered include clinical trial results and milestones for Tinlarebant in Stargardt disease and geographic atrophy patient populations, regulatory designations and approvals from the FDA and international health authorities, pipeline updates related to LBS-009 for metabolic diseases, corporate partnerships and licensing agreements, equity financing and capital markets activities, scientific presentations at ophthalmology and biotechnology conferences, and intellectual property developments protecting the company's anti-RBP4 platform technology.
Investors and patients following Belite Bio should pay particular attention to announcements regarding pivotal trial readouts, regulatory submission timelines, and commercialization strategies for Tinlarebant. The company has received multiple regulatory designations including Orphan Drug, Fast Track, and Breakthrough Therapy status, which may accelerate development timelines and facilitate market entry. As a clinical-stage company with no marketed products, news flow typically centers on clinical data releases, regulatory interactions, and funding activities that support advancement of the pipeline.
The company's expansion beyond ophthalmology into metabolic diseases with LBS-009 represents a strategic diversification that leverages the established safety and pharmacology of RBP4 modulation. News regarding preclinical data, investigational new drug applications, and early-stage clinical development of this program may signal long-term value creation opportunities in large patient populations affected by liver disease, diabetes, and metabolic syndrome.
Belite Bio (NASDAQ: BLTE) has secured US$28.75 million through the exercise of warrants at US$44.14 per share for 651,380 ordinary shares. In exchange for this immediate cash exercise, the company will issue new unregistered warrants for the same number of shares with an exercise price of US$70.00 per share, valid for five years. If these new warrants are fully exercised, they could generate additional gross proceeds of approximately US$45.6 million. The company plans to use the proceeds for general corporate purposes.
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in the American Academy of Ophthalmology Annual Meeting (AAO 2024) from October 18-21, 2024, in Chicago. The company will present data from its completed Phase II adolescent Stargardt disease trial.
Two presentations are scheduled:
- A podium presentation titled "Tinlarebant (LBS-008) for Adolescents with Stargardt Disease" by Dr. Quan Dong Nguyen on October 19, 2024, at 10:33 AM CDT.
- An e-poster presentation titled "Investigation of an Oral Retinol Binding Protein 4 Antagonist in the Treatment of Childhood-onset Stargardt Disease" by Dr. Nathan L Mata, available on-demand.
These presentations will showcase Belite Bio's progress in developing novel therapeutics for Stargardt disease, a degenerative retinal condition with significant unmet medical needs.
Belite Bio, a clinical-stage biopharmaceutical company (NASDAQ: BLTE) focusing on novel therapeutics for degenerative retinal diseases, has announced its participation in the Maxim Group 2024 Healthcare Virtual Summit. Dr. Hendrik P.N. Scholl, the company's Chief Medical Officer, will be part of the 'Ocular Drug Development' panel discussion.
The event is scheduled for Tuesday, October 15, 2024, at 11:00 am ET. Interested parties can access the live panel discussion through Maxim's M-Vest website. For registration and additional information, visitors are directed to https://m-vest.com/events/healthcare-10152024.
This participation underscores Belite Bio's commitment to advancing treatments for unmet medical needs in the field of degenerative retinal diseases.
Belite Bio (NASDAQ: BLTE) has dosed the first patient in the Phase 2/3 DRAGON II trial of Tinlarebant for Stargardt Disease (STGD1) treatment. The trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in about 60 adolescent STGD1 subjects across the U.S., U.K., and Japan. Tinlarebant, an oral therapy designed to reduce vitamin A-based toxin accumulation causing retinal disease, has received Orphan Drug and Sakigake Designation in Japan. The trial follows a completed Phase 1b study in Japan and is part of Belite's efforts to address unmet needs in STGD1 treatment. Simultaneously, Belite's Phase 3 PHOENIX trial for Tinlarebant in Geographic Atrophy (GA) is ongoing with over 200 subjects enrolled.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in three upcoming investor conferences. The executive management team will attend:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024, at 9:30 am ET for a fireside chat.
2. 2024 Cantor Global Healthcare Conference in New York on September 18, 2024, at 3:40 pm ET for a corporate presentation.
3. Deutsche Bank Depositary Receipts Virtual Investor Conference on September 25, 2024, at 11:00 am ET for a virtual corporate presentation.
Webcasts of all presentations will be available on Belite Bio's investor relations website and archived for 90 days after each event.
Belite Bio (NASDAQ: BLTE) has appointed Dr. Hendrik P. N. Scholl as its new Chief Medical Officer. Dr. Scholl is a globally recognized expert in ophthalmology, specializing in Stargardt disease and age-related macular degeneration (AMD). He brings decades of experience to Belite Bio's lead drug candidate, Tinlarebant, which targets these conditions.
Dr. Scholl's impressive career includes founding the Institute of Molecular and Clinical Ophthalmology Basel, serving as Professor of Ophthalmology at the University of Basel, and holding leadership positions at Johns Hopkins University. He is the coordinating principal investigator of the largest natural history study of Stargardt disease and has authored over 280 peer-reviewed articles.
Belite Bio (NASDAQ: BLTE) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Tinlarebant, their novel oral therapy for Stargardt Disease (STGD1) and Geographic Atrophy (GA), is progressing in clinical trials.
2. The DRAGON II trial for STGD1 has completed Phase 1b enrollment with six subjects in Japan.
3. The PHOENIX trial for GA has enrolled approximately 200 subjects.
4. Q2 2024 financials: $112.3 million in cash and equivalents, R&D expenses of $9.1 million, and a net loss of $9.5 million.
5. The company raised $25 million in a registered direct offering in April 2024.
6. Interim analysis from the pivotal Phase 3 DRAGON trial is expected in Q4 2024.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Dr. Nathan Mata, the company's Chief Scientific Officer, will present a corporate update on August 15, 2024, at 7:00 am ET.
The presentation will be available as a webcast under the "Events" tab on Belite Bio's investor relations website. Interested parties can access the replay, which will be archived for 90 days following the presentation date. This event provides an opportunity for Belite Bio to showcase its progress in developing novel therapeutics for unmet medical needs in retinal diseases.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases, has announced a webcast scheduled for August 12, 2024, at 4:30 p.m. Eastern Time. The purpose of this webcast is to discuss the company's financial results for the second quarter ended June 30, 2024, and provide a business update.
Investors and interested parties can access the live webcast through the provided link or via the 'Presentations & Events' section of Belite Bio's Investor Relations website. A replay of the webcast will be available for approximately 90 days after the event, allowing those unable to attend the live session to review the information at their convenience.
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical firm specializing in treatments for degenerative retinal diseases, announced that its Chief Scientific Officer, Dr. Nathan Mata, will present a corporate update at the JonesHealthcare Seaside Summit. The event will take place in Encinitas, CA, on July 15, 2024, at 1:00 pm PT. The presentation will be available via webcast on the Belite Bio website under the 'Events' tab, with a replay accessible for 90 days post-presentation.
FAQ
What is the current stock price of Belite Bio (BLTE)?
What is the market cap of Belite Bio (BLTE)?
